Compare iShares MSCI Australia ETF (EWA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Novavax Inc — how do they compare? iShares MSCI Australia ETF trades at $28.59 (market cap $1.17B), while Novavax Inc trades at $12.72 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, iShares MSCI Australia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Novavax Inc for 59 Days on average.
| EWA | NVAX | |
|---|---|---|
Market Cap | $1.17B | $1.82B |
Volume | 2,121,231 | 6,198,505 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $12.56 |
52-Week Low | $24.95 | $6.22 |
Typical Hold Time | 61 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.56, up 1.17% today, but technical indicators are bearish with all moving averages signaling sell. The ETF provides exposure to Australian equities, heavily weighted toward commodities and financials. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns due to rising oil prices.
The outlook remains cautious amid bearish technicals and macroeconomic headwinds, though some analysts see upside potential from commodity strength. Risks include persistent inflation, tight monetary policy, and reliance on raw material exports. Investors should weigh technical weakness against long-term commodity-driven growth prospects.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
